Back to News
Market Impact: 0.25
Alvotech, LOTTE Biologics Sign Deal For U.S. Biosimilar Manufacturing
Source: Nasdaq
Healthcare & BiotechCompany Fundamentals
Alvotech entered a long-term strategic manufacturing agreement with LOTTE Biologics to increase global supply capacity for its biosimilar medicines. The announcement included no capacity figures or financial terms.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.30
Ticker Sentiment
ALVO0.65
More News
- Former world No. 1 Jon Rahm's lawyer tells court Spaniard is done with LIV Golf after three seasons
- Anthropic will be 'most ridiculous IPO' of year, analyst says
- Levi Strauss hikes profit guidance after tariff refunds, but its sales outlook is less optimistic
- Samsung Q3 profit surges to record high, but misses lofty expectations
- Brazil is having its Argentina moment. How to play it
- Streamex CIO Mitchell Williams sells $35,239 in company stock